XBiotech Inc.
NMS: XBITLive Quote
About XBiotech Inc.
Healthcare
Biotechnology
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
📊 Fundamental Analysis
XBiotech Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -28.2%, which indicates that capital utilization is currently under pressure.
At a current price of $2.33, XBIT currently trades near the bottom of its 52-week range (16%), indicating potential value or weakness (Range: $2.09 - $3.61).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$73.78M
Trailing P/E
--
Forward P/E
17.92
Beta (5Y)
0.83
52W High
$3.61
52W Low
$2.09
Avg Volume
40K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App